Inmune Bio, Inc 8-K, filed Mar 16, 2022
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on March 16, 2022, reporting on events of March 14, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
| (Exact name of registrant as specified in charter) |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On March 14, 2022, INmune Bio, Inc. (the” Company”) issued a press release announcing that it will participate in the 32nd Annual Oppenheimer Health Care Conference and the 2022 Maxim Group Virtual Growth Conference. A copy of this press release is attached is Exhibit 99.1. On March 15, 2022, the Company issued a press release announcing Nine Data Presentations at AD/PDTM 2022 – International Conference on Alzheimer’s and Parkinson’s Diseases. A copy of this press release is attached is Exhibit 99.2.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| 99.1 | Press Release dated March 14, 2022 | |
| 99.2 | Press Release dated march 15, 2022 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: March 15, 2022 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
2
Exhibit 99.1
INmune
Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare
Conference and the 2022 Maxim Group Virtual Growth Conference
Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, MD., President and CEO has been invited to participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference.
Dr Tesi will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference, which is being held virtually on March 15 – 17, 2022.
Event Details
Date: Wednesday, March 16, 2022
Time: 11:20am ET
To set up 1X1 meetings with management, please contact your Oppenheimer representative.
Dr. Tesi will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group during the 2022 Maxim Group Virtual Growth Conference, which is being held virtually on March 28– 30, 2022.
Event Details
Date: Wednesday, March 30, 2022
Time: 11:00am ET
Register: https://m-vest.com/events/2022-virtual-growth-conference.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment resistant depression (XProTM). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Information about Forward-Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
DMoss@INmuneBio.com
(858) 964-3720
Investor Contact:
Core IR
Jason Nelson
info@inmunebio.com
516.842.9614 x-823.
Exhibit 99.2
INmune Bio, Inc. Announces Nine Data Presentations
at AD/PD™
2022 - International Conference on Alzheimer’s and Parkinson’s Diseases
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer’s Disease
Boca Raton, Florida, March 15, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces nine pieces of data, including oral symposia, will be presented at AD/PD™ 2022 - International Conference on Alzheimer’s and Parkinson’s diseases. The AD/PD™ 2022 International Conference is being held from March 15-20 in Barcelona, Spain.
Raymond J. Tesi, Ph.D, Chief Executive Officer of INmune Bio, commented,
“This is the first time many clinician teams in Europe and UK have been exposed to XPro™ and INmune Bio’s approach to treatment of Alzheimer’s Disease,” said RJ Tesi. “These nine presentations show the versatility of XPro™ and the importance of neuroinflammation in the pathogenesis of neurodegenerative disease. The presentations provide a great overview of XPro™ for the treatment of AD, introducing the novel biomarkers INmune is using, and how the results of the Phase I trial provided insight into the design the Phase II trials in mild cognitive impairment and Mild Alzheimer’s.”
Details of the presentations are as follows:
Symposia Oral Presentations:
| ● | MRI Measures of White Matter Pathology in AD Clinical Trials – Case Study from The Xpro1595 Phase 1 Trial in Alzheimer’s Patients with Neuroinflammation (Presentation Time: Thursday, March 17, 2022 - 18:30 PM - 18:45 PM) |
| ● | TMT Calibrator - Combined Tissue and Fluid Proteomics Supports Decision Making in an Alzheimer’s Disease Clinical Trial Program (Presentation Time: Saturday, March 19, 2022 from 09:40 AM - 09:55 AM) |
| ● | Endpoint Selection and Power Estimates for the Primary Cognitive Endpoint in a Phase 2 Trial of Xpro1595 in Alzheimer’s Disease (AD) with Inflammation (ADI) (Presentation Time: Saturday, March 19, 2022 from 17:30 PM - 17:45 PM |
On Demand Presentations:
| ● | O033 / #1305 On-Demand Symposium: A Three-Step Process to Define Phase II Trials Design Using a Patient Enrichment Strategy Using Phase I Data and Public Databases |
| ● | O039 / #1059 On-Demand Symposium: Baseline Assessment Of Novel White Matter Imaging Measures of Neuroinflammation, Axonal Density And Demyelination In Largescale Multicenter ADNI |
Poster Presentations:
| ● | P031 / #1228 Posters: TNF as a Mediator of Immune and Metabolic Alterations in the 5XFAD Mouse Model of Alzheimer’s Disease |
| ● | P105 / #2191 Posters: White Matter (WM) Abnormalities Correlate with CSF Biomarkers of Microglial Activation and Pathological Tau in Alzheimer’s Disease |
| ● | P179 / #1248 Posters: Novel Soluble TNF Inhibitor Improves Outcomes in a Mouse Model of Traumatic Brain Injury Indiced Alzheimer Disease |
| ● | P325 / #1106 Posters: Longitudinal Assessment of Novel White Matter Imaging Measures of Neuroinflammation, Axonal Density and Demyelination in Largescale Multicenter ADNI. |
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trials to determine if it can treat cancer (INB03), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
info@inmunenbio.com
Investor Contact:
Jason Nelson
Core IR
516.842.9614 x-823